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Research Article
Immunohistochemical staining, laser
capture microdissection, and filter-aided
sample preparation-assisted proteomic
analysis of target cell populations within
tissue samples
An important problem involves isolating subpopulations of cells defined by protein mark-
ers in clinical tissue samples for proteomic studies. We describe a method termed
Immunohistochemical staining, laser capture microdissection (LCM) and filter-aided
sample preparation (FASP)-Assisted Proteomic analysis of Target cell populations within
tissue samples (ILFAPT). The principle of ILFAPT is that a target cell population express-
ing a protein of interest can be lit up by immunohistochemical staining and isolated
from tissue sections using LCM for FASP and proteomic analysis. Using this method,
we isolated a small population of CD90+ stem-like cells from glioblastoma multiforme
tissue sections and identified 674 high-confidence (false discovery rate < 0.01) proteins
from 32 nL of CD90+ cells by LC-MS/MS using an Orbitrap Elite mass spectrometer. We
further quantified the relative abundance of proteins identified from equal volumes of
LCM-captured CD90+ and CD90− cells, where 109 differentially expressed proteins were
identified. The major group of these differentially expressed proteins was relevant to cell
adhesion and cellular movement. This ILFAPT method has demonstrated the ability to
provide in-depth proteome analysis of a very small specific cell population within tissues.
It can be broadly applied to the study of target cell populations within clinical specimens.
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1 Introduction
Organs and tissues are composed of heterogeneous cell popu-
lations with different functions. An in-depth proteomic study
of a specific cell population within tissues will improve our
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understanding of its functions at the protein level, and could
even reveal the mechanisms of diseases if the target cell pop-
ulation is from clinical specimens. Some cell populations,
for example, cancer stem cell populations, are of great inter-
est where there is increasing evidence that cancer stem cells
are responsible for tumor generation and ongoing growth
[1, 2], including brain tumors [3–5]. Our recent work has
demonstrated that CD90+ cells within glioblastoma multi-
forme (GBM) exhibit distinct stem cell properties [6]. It is
thus essential to investigate the proteome of this CD90+ cell
population.
A crucial step for proteome research of a target cell pop-
ulation within tissue samples is to isolate this population,
which is often based on specific binding to a marker of
the target population. Several techniques have been devel-
oped to sort different cell populations from tissues, where
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fluorescent-activated cell sorting (FACS) [7] and magnetic-
activated cell sorting (MACS) [8] have been most frequently
used.However, bothFACSandMACSare only suitable to sort
live cells in fresh tissues using cell surface markers, while in-
tracellular markers are not compatible with these techniques.
These limitations impede the application of FACS andMACS
to the study of specific cell populations within clinical tissue
samples.
Laser capture microdissection (LCM) is a powerful tech-
nology that can be used to capture cells from tissue sections
[9]. Most clinical samples are routinely fixed in formalin
where they are readily sectioned and can be used for LCM
analysis. Immunohistochemistry-guided LCM has been de-
veloped for mRNA analysis of specific cell populations in
clinical specimens [10]. Recently, LCM has also been uti-
lized for proteomic analysis of clinical samples. For example,
Patel et al. [11] performed a proteomic analysis of squamous
cell carcinoma of the head and neck tissues and identified
around 700 proteins from 20 000 cells procured from tis-
sue sections. In another study on human breast cancer ep-
ithelial cells [12], around 60 000 cells were captured from
each of 18 tissue samples and 1623 proteins were identified
from these samples. Quantitative analysis of these proteins
resulted in identification of 298 differentially expressed pro-
teins between normal and malignant breast epithelial sam-
ples. Recently, Wisniewski et al. [13] applied a filter-aided
sample preparation (FASP) method to proteomic analysis
of LCM-captured human tissues and greatly improved the
depth of proteome analysis. By adding an additional peptide
fractionation step prior to LC-MS/MS analysis, they accom-
plished a depth of 3600–4400 proteins from each sample
containing 175 nL of collected tissue (5–7 g of peptides).
These studies demonstrated the ability of LCM to assist in
proteomic analysis of tissue samples, which typically con-
tain multiple cell populations; however, they did not demon-
strate analysis of a specific cell population within tissue
samples.
Herein, we describe a method for in-depth proteomic
analysis of a very small number of target cell populations
within tissue samples. We have termed the method as
Immunohistochemical staining, LCM and FASP-Assisted
Proteomic analysis of Target cell populations within tissue
samples (ILFAPT). To guide the precise capture of a tar-
get cell population by LCM, we applied immunohistochem-
ical staining to specifically light up the target population in
tissue sections. After the captured cells were processed by
the FASP method, the resulting peptides were analyzed by
LC-MS/MS. We have demonstrated the application of this
ILFAPT method for proteomic analysis of a small popula-
tion of CD90+ cancer stem cells within GBM tissues, where
674 high-confidence proteins were identified from 32 nL
of LCM captured cells. Further comparison of CD90+ and
CD90− cell populations using a spectral counting method
resulted in identification of 109 differentially expressed
proteins.
2 Materials and methods
2.1 Tissue samples
A fresh primary GBM biopsy was obtained from the Uni-
versity of Michigan University Hospitals with approval
from the Internal Review Board. Tissues were fixed in 4%
paraformaldehyde (PFA) overnight at 4C, cryoprotected with
30% sucrose saturation, and cryoembedded in Tissue-Tek
OCT. Tissues were sectioned in 8 m thickness and stored
at −80C for subsequent use.
2.2 Immunohistochemical staining for CD90+ cells
The PFA-fixed GBM tissue sections were thawed for 20–
30 s and rinsedwith PBS. Endogenous peroxidase activity was
blocked using 6%H2O2 in 80%methanol for 10min. The tis-
sue sections were then blocked with 2% normal goat serum
and incubated with a rabbit anti-human CD90 monoclonal
antibody (1:100 dilution, Abcam, Cambridge, MA, USA) for 2
h, washed with PBS three times (10min each), and incubated
with a goat anti-rabbit biotinylated antibody (Vector Laborato-
ries, Burlingame, CA, USA) for 1 h. The slides were washed
again with PBS three times (10 min each), and immunode-
tection was performed using the VECTASTAIN Elite ABC
system and DAB substrates (Vector Laboratories), where the
expression of antigen CD90 was visualized as a brown color.
Nuclei were lightly counterstained with hematoxylin (blue).
The slides were dehydrated in 70%, 95%, and 100% ethanol
for 30 s each, rinsed in xylene, air-dried, and then placed in a
desiccator overnight to ensure complete drying.
2.3 LCM
CD90+ cells were captured from completely dried tissue sec-
tions using the Veritas Laser Capture Microdissection Sys-
tem (Arcturus, Molecular Devices, CA, USA). CD90+ areas
were selected under a 20× objective and microdissected us-
ing CapSure LCM macro caps. LCM was performed on six
tissue sections and ∼4 mm2 of CD90+ cells were collected.
Equal areas of CD90− cells were also collected, which served
as a control against CD90+ cells.
2.4 Protein extraction and digestion by FASP
Proteins in microdissected cells were extracted and digested
using the FASP protocol [13, 14]. A FFPE-FASPTM Protein
Digestion Kit (Protein Discovery, San Diego, CA, USA) was
used in thiswork. Briefly,microdissected cellswere lysedwith
40 L of protein extraction buffer (0.1 M Tris-HCl, pH 8.0,
0.1 M DTT, 4% SDS) with agitation at 99C for 1 h. The sam-
ples were then centrifuged at 15 000 × g for 10 min and the
clarified lysates were mixed with 200 L of 8 M urea in 0.1 M
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Tris-HCl, pH8.5 in spin filters. The sampleswere centrifuged
at 14 000 × g for 30 min. The step was performed twice.
Then 100 L of 0.05 M iodoacetamide in 8 M urea was
added to the filters and the samples were incubated in the
dark for 20 min, followed by two washes with 100 L of
8 M urea and two washes with 100 L of 50 mM ammonium
bicarbonate. Finally, trypsin was added in 75 L of 50 mM
ammonium bicarbonate to each filter. Protein digestion was
performed at 37C overnight. The released peptides were col-
lected by centrifugation at 14 000 × g for 15 min and evap-
orated to dryness using a SpeedVac concentrator (Thermo
Savant, Milford, MA, USA).
2.5 LC-MS/MS
The peptide mixtures were analyzed by LC-MS/MS using an
Orbitrap Elite mass spectrometer (Thermo Fisher Scientific).
Chromatographic separation of peptides was performed on a
Proxeon EASY nLC II System (Thermo) equipped with an in-
house packed 25 cm column (inner diameter 75 m, Magic
C18 AQ 100 Angstrom, 5 m). Peptides were separated with
a gradient of ACN/water containing 0.3% formic acid at a
flow rate of 400 nL/min. A 130 min linear gradient from 2
to 35% ACN was used. MS spectra were acquired in data-
dependent mode. The resolution of full-scan MS was 120 000
(m/z 400.0–1800.0). The 20 most intense ions in the full
mass scan were selected for MS/MS analysis by CID in the
linear ion trap. The normalized collision energy was set at
35% for MS/MS. MS/MS data were obtained for up to three
ions of charge 2+, 3+, or 4+ detected in the survey scan.
Dynamic exclusion was defined by a list size of 500 features
and exclusion duration of 60 s, and expiration was disabled
to decrease the resequencing of isotope clusters.
2.6 Data analysis
All MS/MS spectra were searched against the UniProtKB/
Swiss-Prot (reviewed, human proteins) protein knowledge-
base release 2012_05. The search was performed using the
SEQUEST algorithm incorporated in the Proteome Discov-
erer software (version 1.1.0.263). The search parameters were
as follows: (i) Fixed modification: carbamidomethyl of cys-
teine; (ii) variable modification: oxidation of methionine; (iii)
maximum missed cleavage sites: 1; (iv) precursor mass tol-
erance: 10 ppm; (v) fragment mass tolerance: 0.8 Da. False
discovery rate (FDR) was set to be < 0.01. The Xcorr values
for all the charge states (+1, +2, and +3) were automatically
adjusted to achieve the predetermined FDR value. If multi-
ple proteins share the same peptide sequences, they will be
reported as a protein group.
We measured the relative abundance between proteins
identified from CD90+ and CD90− cells using the spectral
counting method [15]. The missing values were assigned a
spectral count of 1 to avoid dividing by zero. The spectral
count of each individual protein was normalized by the sum
of the spectral counts per LC-MS/MS run [16]. Spectral count
fold-change was calculated as the ratio of the average spec-
tral count for the target protein. A fold-change ratio of >3.0
was considered as a significant difference between the two
samples.
2.7 Bioinformatic analysis
Gene ontology (GO) annotation for cellular component and
biological process of the identified proteins were performed
using the Database for Annotation, Visualization and Inte-
grated Discovery (DAVID) bioinformatics resources [17, 18].
Protein–protein interaction of the differentially expressed
proteins was analyzed using the STRING database [19]. The
molecular function and biological networks of the differen-
tially expressed proteins were analyzed using the Ingenu-
ity Pathway Analysis software (Ingenuity Systems, Mountain
View, CA, USA).
2.8 Double immunofluorescence analysis of FN1 and
CD90
A tissue microarray (TMA) of formalin-fixed paraffin-
embedded brain tumor and normal tissues was purchased
fromUSBiomax (CatalogNo. T174), which contains one each
of astrocytoma (grade 2), anaplastic astrocytoma (AA, grade
3), glioblastoma (GBM, grade 4) and oligodendroglioma, and
two of normal tissues. The tissue samples originated from
different donors and each sample had four replicates.
The TMAwas dewaxed in xylene for 10 min twice and re-
hydrated through a series of alcohol solutions (100% ethanol
twice, 90% ethanol, 70% ethanol, 5 min each) to water. Anti-
gen retrieval was achieved by boiling the array in citrate buffer
at pH 6.0 (Invitrogen) for 15 min. The TMA was incubated
with 2% normal goat serum in PBS for 1 h at room tempera-
ture to block nonspecific binding. To achieve immunofluores-
cence staining, mouse anti-FN1 (LifeSpan Biosciences, Seat-
tle, WA, USA) and rabbit anti-CD90 (Abcam) were incubated
with the TMA overnight at 4C at a dilution of 1:100. Then
DyLight 488 anti-rabbit IgG (H+L) and DyLight 549 anti-
mouse IgG (H+L) (Vector laboratories) were diluted (1:200)
and incubated with the TMA for 1 h at room temperature.
The nuclei visualization was explored by DAPI counterstain-
ing. Between each step, there were three washes with PBST
for 5 min each. Finally, the TMA was dehydrated in alcohol
(70% ethanol, 90% ethanol, 100% ethanol twice, 5 min each),
and coverslipped using a CC/MountTM permanent mounting
medium (Sigma).
3 Results
3.1 ILFAPT
Our recent work has revealed that CD90 is amarker for GBM-
derived stem-like neurospheres and the CD90+ cell popula-
tion has distinct stem cell properties including self-renewal
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Figure 1. Workflow of the ILFAPT strategy. In this work, the
proteome of CD90+ and CD90− cells within GBM tissues was
compared using the ILFAPT strategy. GBM tissue sections were
immunohistochemically stained using an anti-human CD90 anti-
body, followed by isolation of CD90+ and CD90− cell populations
via laser capture microdissection. After tryptic digestion of pro-
teins in each cell population using an FASP approach, the proteins
were analyzed by LC-MS/MS and spectral counting, which al-
lowed identification of differentially expressed proteins between
CD90+ and CD90− cell populations.
and multilineage differentiation [6, 20]. It is thus essential to
investigate the protein expression of CD90+ cells withinGBM
tissue samples and to investigate the differences at the pro-
teome level betweenCD90+ andCD90− cells, which donot ex-
hibit stem-like properties. To achieve this goal, we have used
an ILFAPT method. The principle of ILFAPT is that a target
cell population expressing a protein of interest can be lit up by
immunohistochemical staining and isolated from tissue sec-
tions using LCM for further FASP-based proteomic analysis.
In this work, the CD90+ population within GBM tis-
sues is our target cell population. The workflow of ILFAPT
is shown in Fig. 1. Briefly, GBM tissue sections were stained
using an anti-human CD90 antibody, and CD90+ cells were
isolated by LCM. CD90− cells were also collected which serve
as a control against CD90+ cells. Proteins fromeach cell popu-
lation were extracted and digested using a FASP method and
further analyzed by LC-MS/MS and spectral counting. The
ILFAPT strategy is not only suitable to study the proteome of
a target cell population within tissues, such as CD90+ cells in
GBM tissues in this work, but also allows us to identify differ-
entially expressed proteins between different cell populations
within tissues (e.g., CD90+ versus CD90− cells).
3.2 Isolation of a CD90+ cell population from GBM
tissue sections
PFA-fixedGBMtissue sectionswere immunohistochemically
stained with an anti-CD90 antibody and counterstained with
hematoxylin. As shown in Fig. 2A, CD90+ cells form vascular-
like structures (brown), which are surrounded by CD90− cells
(blue). CD90+ cells were captured from GBM tissues using
the LCM technology. After LCM, CD90+ cells were efficiently
separated from CD90− cells, where CD90− cells remained
on the tissue slide (Fig. 2B) while most of CD90+ cells were
captured to the LCM cap (Fig. 2C).
CD90+ cells are a small population within GBM tissues.
In the GBM specimen used in this work, the percentage of
CD90+ cells was only ∼2%, where ∼0.7 mm2 of CD90+ cells
were obtained from each ∼36 mm2 tissue section. To collect
an adequate number of cells for the subsequent proteomic
analysis, we combined CD90+ cells captured from six tissue
sections (∼4 mm2). Equal areas of CD90− cells were also
captured from GBM tissues, which serve as a control against
CD90+ cells for quantitative proteomic analysis.
3.3 Identification of proteins from CD90+ and CD90−
cell populations
A FASP method was used to extract and digest proteins from
32 nL (4 mm2 × 8 m) of each of CD90+ and CD90− cell
populations. We estimate that 32 nL of LCM-captured GBM
Figure 2. Isolation of CD90+ cells from
GBM tissues by LCM. A frozen GBM
tissue section was immunohistochem-
ically stained using an anti-CD90 an-
tibody. (A) Before LCM, CD90+ cells
were clearly observedwithin the tissue
section. (B) After LCM, most of CD90+
cells were removed while CD90− cells
remained on the tissue slide. (C) CD90+
cells were captured to the LCM cap.
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Figure 3. A representative MS/MS spectrum of a peptide. The
sequence of the peptide was identified as DLQFVEVTDVK, which
was from fibronectin.
tissue is equivalent to ∼5000 cells, although the number may
not be accurate because different cells vary in size. According
to the relationship between the volume of LCM-captured tis-
sue and the peptide yield measured in a previous study [13],
32 nL of tissue yields around 1.1 g of peptides. The result-
ing peptides were analyzed by three replicates of LC-MS/MS
using an Orbitrap Elite mass spectrometer. When the FDR
was set to be<0.01, the LC-MS/MS analyses resulted in iden-
tification of 674 proteins from CD90+ cells and 1034 proteins
from CD90− cells. The detailed information of these proteins
is listed in Supporting Information Table S1. As an example,
Fig. 3 shows a representative MS/MS spectrum of a peptide
from fibronectin.
GO cellular component annotation (Fig. 4A) showed that
these proteins were primarily located to the cytosol, nucleus,
and cytoskeleton. A major difference in subcellular location
between the two cell populations was that the percentage
of extracellular proteins was much lower for CD90+ cells
compared with CD90− cells. The GO biological process an-
notation (Fig. 4B) revealed that 0.7% of identified proteins
were relevant to cell adhesion for CD90+ cells, compared
with 5.7% for CD90− cells. This was paralleled by the cor-
responding decrease of extracellular proteins in CD90+ cells
where a large proportion of cell adhesion-related proteins are
located in the extracellular matrix.
We evaluated the reproducibility of three replicates of
LC-MS/MS analyses using R2 values from linear regression
for spectral counts of identified proteins. TheR2 values for the
measurements of both CD90+ (Fig. 5A and 5B) and CD90−
(Fig. 5C and 5D) cells were ∼0.99, which indicates that the
LC-MS/MS analyses were highly reproducible in this work.
We further placed all the identified proteins from three repli-
cates of LC-MS/MS into an unsupervised hierarchical cluster-
ing (Fig. 5E). Consequently, the clustering algorithmgrouped
the analyses of each cell population together. This suggests
that CD90+ cells can be separated from CD90− cells based on
the spectral counts of identified proteins.
Figure 4. Gene ontology annotation of identified proteins. Comparison of subcellular location (A) and biological process (B) annotations of
proteins identified from CD90+ and CD90− cells. Subcellular location (C) and biological process (D) annotations of differentially expressed
proteins. Gene ontology cellular component and biological process terms were derived using the DAVID bioinformatics database.
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Figure 5. Reproducibility and hierarchical clustering of triplicate LC-MS/MS experiments. Both reproducibility and hierarchical clustering
assays were based on the spectral count information of identified proteins from each LC-MS/MS analysis. (A and B) Correlation between
LC-MS/MS analyses of CD90+ cells. (C and D) Correlation between LC-MS/MS analyses of CD90− cells. (E) Hierarchical clustering of
triplicate LC-MS/MS analyses of CD90+ and CD90− cells, where each column indicates an individual LC-MS/MS analysis of each cell
population, and each row indicates an identified protein. The number of spectral count increased from red to purple. The Pearson
correlation coefficients were indicated at each branching point.
3.4 Differentially expressed proteins between CD90+
and CD90− cell populations
We applied a spectral counting method to quantify the rel-
ative protein abundance between CD90+ and CD90− cells
isolated from GBM clinical samples. To minimize the varia-
tion among different replicates of LC-MS/MS analyses, we
normalized the spectral count of each individual protein
by the sum of the spectral counts per LC-MS/MS analysis.
When the cut-off criteria were set with a fold-change ratio
of >3.0 and a p value of <0.05, a total of 109 differentially
expressed proteins were identified (Supporting Information
Table S2). GO annotation revealed that the major subcellular
locations of these proteins were extracellular (31.1%), cytosol
(22.6%), and cytoskeleton (19.8%) (Fig. 4C). These differen-
tially expressed proteins were involved in diverse biological
processes, such as cell adhesion (12.3%), protein localization
(12.3%), macromolecular complex assembly (9.4%), ribonu-
cleotide metabolic process (8.5%), defense response (8.5%),
and so on.
We analyzed protein–protein interactions among the dif-
ferentially expressed proteins using the STRING database,
which integrates interaction data fromgenomic context, high-
throughput experiments, coexpression, and previous knowl-
edge. When the confidence score was set to be higher than
0.7, a high-confidence protein–protein interaction network
was generated (Fig. 6A). This network contains 58 high-
confidence interactions for 39 differentially expressed pro-
teins. The detailed information of these proteins is listed in
Table 1. Note that among the 39 proteins, 19 are extracellular
proteins and 8 are cytoskeletal proteins. Interestingly, the ex-
tracellular protein fibronectin (FN1) is imported as a central
node to generate this network by STRING, suggesting that
FN1 may play an important role in this network.
We further analyzed the function and potential pathways
of the differentially expressed proteins using the Ingenu-
ity Pathway Analysis software and identified a high-scoring
(score 35) biological network (Fig. 6B). Twenty-one proteins
were involved in this network, which is relevant to cell–cell
signaling, cell adhesion, and cellular movement. All 21 pro-
teins were downregulated in CD90+ cells. Consistent with the
STRING analysis, most of these proteins were extracellular
and cytoskeletal proteins (Table 2).
3.5 Double immunofluorescence analysis of tissue
microarray with FN1 and CD90
To further validate the expression of fibronectin (FN1) in
CD90+ cells of GBM tissues, double immunofluorescence
staining of FN1 and CD90 was explored on a brain TMA.
The staining was consistent with our previous publication
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Figure 6. Protein interaction network generated from the differ-
entially expressed proteins. (A) High-confidence protein–protein
interaction network derived from the STRING database. Each
node represents a protein, and each edge represents an inter-
action. (B) Biological network generated by Ingenuity Pathway
Analysis. The functions of the network include cell–cell signal-
ing, cell adhesion, and cellularmovement. Solid arrows represent
known direct interactions, and dotted arrows represent indirect
interactions. Green represents the differentially expressed pro-
teins identified in this work; White indicates proteins that were
not identified in this study but related to the network.
[6], where CD90 was not detected in normal brain and astro-
cytoma grade 2 samples (data not shown), whereas strong
staining of CD90 was observed in anaplastic astrocytoma
grade 3 and GBM grade 4 samples, as shown in Support-
ing Information Fig. S1. The expression of fibronectin (FN1)
was also highly elevated in anaplastic astrocytoma grade 3 and
GBM samples compared to normal and astrocytoma grade 2
samples. Interestingly, as shown in Supporting Information
Fig. S1, FN1 was coexpressed with CD90 in grade 3 tumor;
however, the localization of FN1 and CD90 was separated in
GBM tissue, indicating that FN1 expression in CD90+ cells
was dramatically decreased. The significant downregulation
of FN1 in CD90+ GBM cells was consistent with the result
observed in our MS analysis.
4 Discussion
The challenge for investigating the proteome of a target cell
population expressing a protein of interest within clinical
tissue samples is to specifically isolate the target cells from
the tissues. FACS and MACS have been extensively used to
sort different cell populations (especially cancer stem cells)
from fresh tissues. However, the application of FACS and
MACS is limited by the sample source because they are only
suitable for sorting live cells from fresh tissues. Neither of
these methods can be used to sort cells from the vast major-
ity of clinical tissue samples, which are fixed with formalin
or similar reagents. In this study, we developed an ILFAPT
method to isolate target cell populations from fixed tissue
sections for proteomic analysis. The method is based on the
hypothesis that a target cell population within tissues can
be specifically lit up by immunohistochemical staining with
an antibody against a marker for this population and cap-
tured from tissue sections via the LCM technology. Com-
pared with FACS and MACS, another advantage of ILFAPT
is that antibodies against both cell surface and intracellular
markers of target cell populations are compatible with this
method.
We have applied the ILFAPT method to proteomic anal-
ysis of a CD90+ cell population within GBM tissues, which
has been shown to be a stem-like cell population in our recent
work [6]. We found that the method allowed efficient capture
of CD90+ cells and effective separation of CD90+ and CD90−
cell populations (Fig. 2). Analysis of∼1.1g of peptides from
32 nL of PFA-fixed CD90+ cells over three LC-MS/MS runs
resulted in identification of 674 high-confidence (FDR< 0.01)
proteins. Considering the extremely small amount of sample
for each MS analysis, the number is reasonable compared
with other studies using similar numbers of cells [21, 22].
We also compared the protein expression between
CD90+ and CD90− cells, and more proteins were identi-
fied from CD90− cells. A possible reason is that CD90−
cells contain multiple cell populations, which makes the pro-
tein components of CD90− cells more complex than those
of CD90+ cells. Also, the shapes and sizes of different cell
populations within tissues are highly heterogeneous. The
label-free quantitation resulted in identification of 109 dif-
ferentially expressed proteins, where 95 were downregulated
in the CD90+ cells. It is possible that the CD90 antibody and
the corresponding secondary antibody remaining within the
CD90+ cells after LCM could lead to partial ionization sup-
pression of peptide ions in the CD90+ cell group. However,
considering the low abundance of CD90 within these cells,
the amount of antibodies should be very low and have lim-
ited effect to suppress ionization of peptide ions. The “house-
keeping” protein beta-actin was not differentially expressed
between CD90+ and CD90− cells, where the CD90+/CD90−
fold-change ratio was 0.97 (data not shown).
The major groups of differentially expressed proteins are
extracellular and cytoskeletal proteins associated with cell ad-
hesion, cell signaling, and cellular movement (Figs. 4 and
6). The downregulation of this group of proteins in CD90+
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Table 1. Differentially expressed proteins involved in the STRING network
Accession Gene Protein name Fold (CD90+/CD90−) Location p-value
P04745 AMY1B Alpha-amylase 1 28.099 Extracellular 5.1E-06
P37198 NUP62 Nuclear pore glycoprotein p62 (Nup62) 0.322 Nuclear 0.00082
P68871 HBB Hemoglobin subunit beta 0.322 Extracellular 7.1E-05
P01834 HCAK1 Ig kappa chain C region 0.318 Extracellular 0.00405
Q9Y6B6 SAR1B GTP-binding protein SAR1b 0.304 Golgi 0.00307
P67936 TPM4 Tropomyosin alpha-4 chain 0.288 Cytoskeleton 0.01538
P98160 HSPG2 Basement membrane-specific heparan sulfate proteoglycan core protein 0.288 Extracellular 0.01075
Q05682 CALD1 Caldesmon 0.272 Cytoskeleton 8.3E-05
P15104 GLUL Glutamine synthetase 0.271 Cytosol 0.00035
Q6PCB0 VWA1 von Willebrand factor A domain-containing protein 1 0.259 Extracellular 0.02378
P62834 RAP1A Ras-related protein Rap-1A 0.258 Membrane 4.8E-05
P01871 IGHM Ig mu chain C region 0.256 Extracellular 0.00089
P0C0L4 C4B Complement C4-A 0.246 Extracellular 0.00057
P31025 LCN1 Lipocalin-1 0.233 Extracellular 0.04474
P60953 CDC42 Cell division control protein 42 homolog 0.232 Cytoskeleton 0.00072
Q16851 UGP2 UTP–glucose-1-phosphate uridylyltransferase 0.227 Cytosol 0.00326
P07205 PGK2 Phosphoglycerate kinase 2 0.206 Cytosol 0.00069
P19367 HK1 Hexokinase-1 0.206 Mitochondrion 0.00244
P01009 SERPINA1 Alpha-1-antitrypsin (Serpin A1) 0.191 Extracellular 0.01601
P00738 HP Haptoglobin 0.172 Extracellular 2.8E-07
P02452 COL1A1 Collagen alpha-1 0.172 Extracellular 0.00017
P01024 C3 Complement C3 0.169 Extracellular 0.00207
Q02218 OGDH 2-oxoglutarate dehydrogenase 0.157 Mitochondrion 0.00051
P12111 COL6A3 Collagen alpha-3(VI) chain 0.153 Extracellular 0.02814
P10909 CLU Clusterin 0.140 Extracellular 0.00292
P35221 CTNNA1 Catenin alpha-1 0.139 Cytoskeleton 0.00091
P18206 VCL Vinculin 0.139 Cytoskeleton 0.00047
P01876 IGHA1 Ig alpha-1 chain C region 0.135 Cytoskeleton 0.00047
P21796 VDAC1 Voltage-dependent anion-selective channel protein 1 0.133 Membrane 0.00391
P07951 TPM2 Tropomyosin beta chain 0.129 Cytoskeleton 0.00065
P01833 PIGR Polymeric immunoglobulin receptor 0.098 Membrane 0.0011
P08123 COL1A2 Collagen alpha-2(I) chain 0.092 Extracellular 0.00166
P02751 FN1 Fibronectin 0.071 Extracellular 0.00047
P02647 APOA1 Apolipoprotein A-I 0.071 Extracellular 7.8E-05
P50213 IDH3A Isocitrate dehydrogenase [NAD] subunit alpha 0.067 Mitochondrion 8.6E-05
P12109 COL6A1 Collagen alpha-1(VI) chain 0.066 Extracellular 4.3E-05
P50454 SERPINH1 Serpin H1 0.058 ER 1.3E-05
O43707 ACTN4 Alpha-actinin-4 0.047 Cytoskeleton 6.7E-05
P02788 LTF Lactotransferrin 0.030 Extracellular 0.0006
cells may play a critical role in maintaining the undifferenti-
ated status of CD90+ cancer stem cells. The results are similar
to the findings of a previous study where cell migration–
related genes are downregulated in CD15+ brain tumor stem
cells [23]. As shown in Fig. 6A, the extracellular protein fi-
bronectin (FN1) seemed to be a key protein in this network.
Immunohistochemical staining of a TMA revealed that FN1
was coexpressed with CD90 in grade 3 tumor, however, the
localization of FN1 and CD90 was separated in GBM tis-
sue, indicating that FN1 expression in CD90+ GBM cells was
dramatically decreased. Fibronectin is involved in cell adhe-
sion and cell motility, and the fibronectin polymer super-
fibronectin inhibits tumor growth and angiogenesis [24, 25].
We have previously demonstrated that CD90+ cells have stem
cell properties and are colocalized with tumor vasculature
within GBM tissues [6]. The downregulation of fibronectin
in CD90+ cells may play an important role in promoting the
growth of these cells and the formation of GBM vasculature.
The major advantage of ILFAPT is that it allows spe-
cific and deep proteome analysis of target cell populations
within clinical specimens. The method combines the spe-
cific staining of the antibody-based immunohistochemistry
technology, the precise capture of target cells by LCM, and
the efficient extraction and digestion of minute amounts of
protein by FASP. In addition, ILFAPT overcomes the limited
availability of fresh tissue samples and is able to accommo-
date the majority of clinical specimens. Therefore, ILFAPT
could be an important tool for proteome analysis of target
cell populations of clinical specimens.
Antibodies and blocking serum used in ILFAPT for ef-
ficient isolation of target cell populations from clinical spec-
imens do not affect protein identification in the subsequent
C© 2013 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.electrophoresis-journal.com
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Table 2. Differentially expressed proteins in the Ingenuity Pathway Analysis (IPA) network which are relevant to cell–cell signaling, cell
adhesion, and cellular movement
Accession Gene Protein name Fold (CD90+/CD90−) Location p-value
P37198 NUP62 Nuclear pore glycoprotein p62 (Nup62) 0.322 Nuclear 0.00082
Q05682 CALD1 Caldesmon 0.272 Cytoskeleton 8.3E-05
P62834 RAP1A Ras-related protein Rap-1A 0.258 Membrane 4.8E-05
P0C0L4 C4B Complement C4-A 0.246 Extracellular 0.00057
Q15149 PLEC Plectin 0.240 Cytoskeleton 0.02222
P60953 CDC42 Cell division control protein 42 homolog 0.232 Cytoskeleton 0.00072
Q9HC84 MUC5B Mucin-5B (MUC-5B) (Cervical mucin) 0.226 Extracellular 0.03887
P16615 ATP2A2 Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 0.220 ER 0.00093
P01009 SERPINA1 Alpha-1-antitrypsin (Serpin A1) 0.191 Extracellular 0.01601
P04632 CAPNS1 Calpain small subunit 1 0.172 Membrane 0.00012
P02452 COL1A1 Collagen alpha-1 0.172 Extracellular 0.00017
P01024 C3 Complement C3 0.169 Extracellular 0.00207
P12111 COL6A3 Collagen alpha-3(VI) chain 0.153 Extracellular 0.02814
P10909 CLU Clusterin 0.140 Extracellular 0.00292
P18206 VCL Vinculin 0.139 Cytoskeleton 0.00047
P07951 TPM2 Tropomyosin beta chain 0.129 Cytoskeleton 0.00065
P35241 RDX Radixin 0.076 Cytoskeleton 0.00058
P02751 FN1 Fibronectin 0.071 Extracellular 0.00047
P02647 APOA1 Apolipoprotein A-I 0.071 Extracellular 7.8E-05
P12109 COL6A1 Collagen alpha-1(VI) chain 0.066 Extracellular 4.3E-05
P02788 LTF Lactotransferrin 0.030 Extracellular 0.0006
LC-MS/MS analysis. The antibodies or blocking serum are
from a variety of animal species rather than human, for
example, the anti-CD90 antibody and blocking serum ap-
plied in this study were from rabbit and goat, respectively.
However, the tissue samples were from human and in the
MS/MS data analysis, all the spectra were searched against
a human protein database. Therefore, the rabbit or goat pro-
teins should be excluded from the proteins identified. More-
over, three washes with PBS after incubation with primary
and secondary antibodies remove most animal proteins from
the slides. Furthermore, Mouledous et al. had demonstrated
that the immunostaining process had minimal effect on pro-
tein identification by comparing 2DE results obtained from
immunostained LCM brain tissue sections against the extra-
cellular signal-regulated kinases (ERK 1 and 2, as these pro-
teins are highly and ubiquitously expressed throughout the
brain) to those obtained from unstained, dissected samples
[26].
A potential issue for application of ILFAPT to quantita-
tive analysis of very small amounts of sample is that the total
protein amount of each sample is based on the volume of each
cell population where the protein concentration is too low to
be determined using traditional methods. However, the den-
sity of different cell populations within tissues may be differ-
ent. This will cause bias in quantitation of proteins between
different samples. In order to reduce the bias, we normalized
the spectral count of each protein by the sum of the spectral
counts of eachMS analysis, and set the fold-change threshold
to a relatively high value of 3. Development of ultrasensitive
protein concentration determinationmethods will greatly im-
prove the performance of ILFAPT on quantitative proteomic
studies.
In summary, we have described an ILFAPT method,
which provided efficient isolation of target cell populations
from fixed clinical specimens and in-depth proteome anal-
ysis of a very small number of these cell populations. The
ILFAPTmethod is particularly suitable for proteome research
of cancer stem cell populations expressing unique markers.
Comparative analysis of different cancer stem cell popula-
tions using ILFAPT could identify novel biomarkers and re-
veal the molecular and functional differences between these
populations.
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